Dr. Sarah Premji reviews four key studies presented at ESMO 2026 exploring treatment strategies for hormone receptor-positive, HER2-negative advanced breast cancer. She highlights updated VIKTORIA-1 findings demonstrating improved progression-free survival with gedatolisib-based regimens in patients with PIK3CA mutations, including those with visceral metastases. The presentation also examines FOURLIGHT-1, where the selective CDK4 inhibitor atirmociclib improved progression-free survival following prior CDK4/6 inhibitor therapy, and KEYNOTE-B49, which demonstrated a modest progression-free survival benefit with pembrolizumab plus chemotherapy in PD-L1-positive disease. Dr. Premji concludes with final overall survival findings from postMONARCH, highlighting the continued role of abemaciclib plus fulvestrant after CDK4/6 inhibitor progression despite the absence of a statistically significant overall survival benefit.
Transcript:
Dr. Premji: Hello, everyone. My name is Sarah Premji. I’m the Assistant Director of Breast Cancer Research at Sarah Cannon Research Institute in Nashville, Tennessee, and I’m excited to be here to discuss some hormone-positive metastatic breast cancer updates from ESMO 2026. This is not all-encompassing, but I did pick four key abstracts to review with us today.
So the first one is VIKTORIA-1, updated results of a randomized, open-label Phase 3 study of gedatolisib plus fulvestrant, with or without palbociclib, versus standard of care in patients with hormone-positive, HER2-negative advanced breast cancer, with a focus on Study 2 and specific efficacy cohorts. So to remind everybody, gedatolisib is a PAM pathway inhibitor, meaning it inhibits PI3K, mTORC1, and mTORC2.
Study 2 of VIKTORIA-1 was first presented at ASCO in June 2026, which showed that in the PIK3CA-mutated population, there was a median PFS benefit with the triplet to 11.1 months, with a hazard ratio of 0.50, versus 5.6 months. And with the doublet, the median PFS was 11.3 months versus 5.6 months, with a hazard ratio of 0.51.But in this study here, the focus is these patients with baseline liver and lung metastases. So ultimately, what we see is that there was an improvement in median PFS regardless of liver metastases. In those patients without liver metastases, median PFS was improved from 9 months to 21.5 months. In those patients with liver metastases, median PFS was improved from 4.6 months to 9.1 months. And there is a similar trend with the doublet, but there’s caution, as there were only 52 patients included in this part of the trial. The combination also improved median PFS regardless of visceral metastases overall. So in those patients without visceral metastases, the improvement in median PFS was from 9.2 months to 21.5 months, with a hazard ratio of 0.38. And in those patients with visceral metastases, there was an improvement in median PFS from 5.6 months to 9.8 months. And here, the caution remains about the doublet.
In Study 2, the overall response rate was higher with the gedatolisib triplet at 59%, and 43% with the doublet. In Study 1, which was compared here, the overall response rate with the gedatolisib triplet was 39%, or 34% with the doublet. But there are very similar durations of response in both Study 1 and Study 2, about 19 months with the triplet in Study 2, and then 27 months with the doublet in Study 2. So looking here at duration of response more closely, this was 19.4 months with the triplet and 27.8 months with the doublet. But note again that Study 2 was a smaller cohort, about a third of the size of the triplet cohort, so we do see wider confidence intervals here. Regarding safety, there was a 5% discontinuation rate in the triplet arm due to adverse events, compared to 4% in the doublet, compared to 19% discontinuation rates with alpelisib in the control arm. And ultimately, we do see here that stomatitis, which was a big question in the trial, occurred in about 60% with the doublet and triplet compared to about 30% with alpelisib. And this was important because this was despite the use of steroid mouthwash, which was mandated.
But we can see here that this was mostly transient. There was improvement over time. By the second cycle, less than 3% had grade 3 stomatitis, which is interpreted as interfering with oral intake, and most of these improved within a few weeks. So here’s a summarization of the key efficacy by median PFS and overall response rates by key subgroups. The conclusions being that gedatolisib plus fulvestrant, with or without palbociclib, did statistically significantly improve median PFS compared with alpelisib plus fulvestrant in patients with and without visceral or liver metastases. Here, with the focus on these patients with PIK3CA mutations, there were robust overall response rates with durable responses.Discontinuation rates overall were low, and the benefits did persist over time, with stomatitis thankfully dropping over time as well. All right, the next study. This was really great data to see, the FOURLIGHT-1 study. So this was a randomized Phase 2 study that was looking at patients who received a CDK4-selective inhibitor called atirmociclib plus fulvestrant, in those patients who had progressed on a CDK4/6 inhibitor.
So the thought here behind the CDK4 inhibitor is that if you more potently inhibit the CDK4-cyclin D1 complex, you more potently block RB phosphorylation, and you spare some of that hematologic toxicity of inhibiting CDK6. So ultimately, this is what they were looking at with this agent, atirmociclib, after progression on a CDK4/6 inhibitor. These were patients with hormone-positive, HER2-negative advanced breast cancer who had received a prior CDK4/6 inhibitor in either the adjuvant or neoadjuvant setting or the first-line metastatic setting. These patients were randomized to receive atirmociclib plus fulvestrant compared to either fulvestrant or everolimus plus exemestane, which was great to see a doublet included in the control arm. And the primary endpoint was investigator-assessed median PFS. So ultimately, some of the trial population characteristics to include are that about 38% of these patients were ESR1-mutated, about 41% of the population was PIK3CA-mutated, and about 75% of patients had over 12 months of time on their prior CDK4/6 inhibitor. And here we can see that median PFS was improved from 6.6 to 9.4 months, with a hazard ratio of 0.60, and this was statistically significant. So we can see here that the benefit favored atirmociclib across all subgroups.
Ultimately, almost all patients did have at least one treatment-related adverse event. The most common, despite looking at a CDK4-selective inhibitor, were neutropenia and leukopenia, but there was 22% grade 3 neutropenia. There was no febrile neutropenia or QT prolongation with atirmociclib. So this ultimately is being studied in larger populations. Atirmociclib is a potential first-in-class, highly selective CDK4 inhibitor that did show improvement in combination with fulvestrant. It is now being studied in various other combinations, including FOURLIGHT-3, testing atirmociclib in the first line with endocrine therapy and then evaluating atirmociclib in other patient populations as well, which will be exciting to see. Okay, moving on to KEYNOTE-B49. So this was a Phase 3 randomized, double-blind study looking at pembrolizumab versus placebo plus chemotherapy in patients with hormone-positive, HER2-negative, PD-L1-positive advanced breast cancer. Ultimately, this has been a question in the field for a while. We’ve all wondered about the role of immunotherapy in hormone-positive metastatic breast cancer.
These are often considered immune-cold tumors, and it was unclear how well immunotherapy was working in these patient populations. We do have some data from the early-stage setting from trials such as KEYNOTE-756 and CheckMate 7FL, which do show some benefit in tumors with lower ER expression. But ultimately, this was a trial specifically looking at the metastatic population and those that had a definition of PD-L1 CPS greater than or equal to 1. All of these patients had to have progressed on greater than or equal to one line of endocrine therapy with a CDK4/6 inhibitor. If no CDK4/6 inhibitor was given, relapse had to be within 24 months of primary surgery while on adjuvant endocrine therapy, or progression within six months of starting first-line therapy. And patients were randomized one-to-one to receive pembrolizumab plus chemotherapy or placebo plus chemotherapy. And the chemotherapy included a taxane versus liposomal doxorubicin versus capecitabine. And the taxane could be paclitaxel or nab-paclitaxel, with the primary endpoint being progression-free survival. So ultimately, you can see here a little bit more about baseline characteristics.
We can see that the majority of patients had a PD-L1 CPS of 1 to 9. There was a small cohort, a little over 20% of patients, who had a PD-L1 CPS greater than or equal to 10. Capecitabine was the most common chemotherapy of physician’s choice here. Next was nab-paclitaxel and paclitaxel combined. Over 80% of patients had visceral metastases. The majority of the patients had an ER over 10%, and almost all patients had received a prior CDK4/6 inhibitor. So here we can see PFS by blinded independent central review. For CPS greater than or equal to 1, there was a statistically significant improvement in median PFS from 6 to 6.7 months, with a hazard ratio of 0.74 at both time points. And this was the interim analysis and the final analysis. We can see here that, of course, while the difference is small, there was a quick drop-off in both arms of patients who unfortunately did face progression. And then when looking at the tail of the curve, there are some patients who do have a durable response, with almost a tripling of those patients who are free from progression at 24 months.
And then looking here specifically at a secondary endpoint, which was median PFS by CPS greater than or equal to 10, which remember made up a little bit over 20% of the population. We do see here that median PFS was improved from 4.4 months to 7.5 months, and here we see a hazard ratio of 0.59. Of course, there’s a caution that this was a small population, but still great to see that bigger difference there. So ultimately, looking at overall survival, which is a key secondary endpoint, this was approximately identical overall survival in both arms, about 22 months for those patients. And notice here that while the difference is not considered statistically significant and the hazard ratio is over 1, when looking here at CPS greater than or equal to 10, the hazard ratio did shift a little bit to the left, even though the median overall survival does appear to be largely the same. And there can be a lot of thoughts as to the subsequent therapy that patients received, which certainly can affect overall survival in these populations. So ultimately, looking here at immune-mediated adverse events, the most common was thyroid disorders, which we often do see.
All other immune-related adverse events were less than 5%. Nonetheless, pneumonitis was represented here. So ultimately, the key conclusion is that the KEYNOTE-B49 study evaluated immunotherapy plus chemotherapy in an endocrine-resistant, PD-L1-positive population, defined by CPS greater than or equal to 1, with advanced hormone-positive breast cancer. We did see an improvement in median PFS versus placebo plus chemotherapy in those patients with positive PD-L1, with a greater numerical benefit in those with a higher CPS score greater than or equal to 10, noting that this was a smaller population. There was not a statistically significant improvement in overall survival, but caution that overall survival certainly can be limited by subsequent therapies. And ongoing studies are looking at other types of therapy in combination with immunotherapy in this patient population. Okay, the last study that I’m going over here is the postMONARCH trial, which was looking at abemaciclib plus fulvestrant versus placebo plus fulvestrant for hormone-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.
So ultimately, this was the first randomized Phase 3 placebo-controlled trial that did demonstrate that continuation of CDK4/6 inhibition with abemaciclib plus fulvestrant improved median PFS compared to placebo plus fulvestrant in those patients who had progressed on their first-line aromatase inhibitor plus CDK4/6 inhibitor. In that study, the hazard ratio was 0.73, which was considered statistically significant. And this study at ESMO focused on the prespecified final overall survival. So again, these were patients with advanced breast cancer who had disease progression on a CDK4/6 inhibitor plus an aromatase inhibitor, or they had disease recurrence on or after CDK4/6 inhibitor plus endocrine therapy in the adjuvant setting, and no other therapy for advanced breast cancer. Patients were randomized one-to-one to receive abemaciclib plus fulvestrant versus placebo plus fulvestrant. And here, as we mentioned, we’re going over the overall survival results. So ultimately, you can see here that there was a numerical improvement by a delta of 7.5 months with the use of abemaciclib plus fulvestrant. This was not statistically significant. The hazard ratio was 0.80.
This overall survival benefit did persist across all prespecified subgroups, and the updated PFS was consistent with the primary analysis. So by investigator assessment, median PFS did improve from 5.3 months to 5.9 months, with a hazard ratio of 0.78. And when looking at a secondary endpoint, which was blinded independent central review, PFS was improved from 5.6 months to 13.8 months, with a hazard ratio of 0.60. So ultimately, the conclusion here is that overall survival numerically favored abemaciclib plus fulvestrant following disease progression on a prior aromatase inhibitor with a CDK4/6 inhibitor, even though the difference was not statistically significant. This overall survival trend was consistent across prespecified subgroups, which were balanced, and the overall survival trend is consistent with PFS outcomes, with no new safety signals. So this continues to be an option to consider for patients who progress, in the armamentarium of options that we have in the post-CDK4/6 inhibitor population for hormone-positive advanced breast cancer.
